Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Beats Expectations By $999.35 EPS

Structure Therapeutics (NASDAQ:GPCR) issued its quarterly earnings results on Thursday. The company reported $999.00 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $999.35, reports.

Structure Therapeutics Price Performance

Structure Therapeutics stock traded down $1.78 during trading on Thursday, reaching $64.75. The company had a trading volume of 939,537 shares, compared to its average volume of 880,593. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90. The firm’s 50-day simple moving average is $75.45 and its 200 day simple moving average is $46.22.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds have recently bought and sold shares of GPCR. State of Wyoming purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Structure Therapeutics in the fourth quarter valued at approximately $127,000. Raymond James Financial Inc. purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $129,000. Cibc World Market Inc. purchased a new position in Structure Therapeutics in the 4th quarter worth $226,000. Finally, Engineers Gate Manager LP purchased a new position in Structure Therapeutics during the 2nd quarter worth approximately $329,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GPCR. Stifel Nicolaus boosted their price target on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. JPMorgan Chase & Co. increased their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, January 22nd. BMO Capital Markets reissued an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Citizens Jmp boosted their price objective on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research note on Friday, December 12th. Finally, Morgan Stanley lifted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $106.20.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.